Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 151 to 165 of 207 results for arthritis

  1. Automated ankle brachial pressure index measurement devices to detect peripheral arterial disease in people with leg ulcers (DG52)

    Evidence-based recommendations on automated ankle brachial pressure index measurement devices to detect peripheral arterial disease in people with leg ulcers

    Diagnostics guidance
    Published
    24 May 2023
    View recommendations

    Sections for DG52

  2. Gouty arthritis: canakinumab (ESNM23)

    This advice has been updated and replaced by NICE guideline NG219.

    Evidence summary
    Published
    23 July 2013

  3. Non-Hodgkin's lymphoma: rituximab subcutaneous injection (ESNM46)

    Summary of the evidence on rituximab subcutaneous injection for non-Hodgkin's lymphoma in adults to inform local NHS planning and decision-making

    Evidence summary
    Published
    9 September 2014

  4. Cystic fibrosis: diagnosis and management (NG78)

    This guideline covers diagnosing and managing cystic fibrosis. It specifies how to monitor the condition and manage the symptoms to improve quality of life. There are also detailed recommendations on treating the most common infections in people with cystic fibrosis.

    NICE guideline
    Published
    25 October 2017
    View recommendations

    Sections for NG78

  5. Rheumatoid arthritis in adults: management (CG79)

    This guidance has been updated and replaced by NICE guideline NG100.

    Clinical guideline
    Last updated
    9 December 2015

  6. The clinical effectiveness and cost effectiveness of etanercept and infliximab for rheumatoid arthritis and juvenile poly-articular idiopathic arthritis (TA36)

    This guidance has been replaced by NICE technology appraisal guidance 130 and NICE technology appraisal guidance 195.

    Technology appraisal guidance
    Published
    27 March 2002

  7. Tocilizumab for the treatment of rheumatoid arthritis (TA198)

    This guidance has been updated and replaced by NICE technology appraisal guidance 247.

    Technology appraisal guidance
    Published
    25 August 2010

  8. Adalimumab for the treatment of psoriatic arthritis (TA125)

    This guidance has been updated and replaced by NICE technology appraisal guidance 199.

    Technology appraisal guidance
    Published
    22 August 2007

  9. Rituximab for the treatment of rheumatoid arthritis (TA126)

    This guidance has been updated and replaced by NICE technology appraisal guidance 195.

    Technology appraisal guidance
    Published
    22 August 2007

  10. Abatacept for the treatment of rheumatoid arthritis (TA141)

    This appraisal has been updated and replaced by NICE technology appraisal guidance 195.

    Technology appraisal guidance
    Published
    23 April 2008

  11. Meningitis (bacterial) and meningococcal disease: recognition, diagnosis and management (NG240)

    This guideline covers recognising, diagnosing and managing bacterial meningitis and meningococcal disease in babies, children, young people and adults. It aims to reduce death and disability by helping healthcare professionals recognise meningitis and treat it quickly and effectively.

    NICE guideline
    Published
    19 March 2024
    View recommendations

    Sections for NG240

  12. Filgotinib for treating moderately to severely active Crohn's disease [ID6236]

    Discontinued [GID-TA11244]

    Technology appraisal guidance
    Discontinued

  13. QuikRead go for C-reactive protein testing in primary care (MIB78)

    NICE has developed a medtech innovation briefing (MIB) on the QuikRead go for C-reactive protein testing in primary care

    Medtech innovation briefing
    Published
    14 September 2016

  14. Mobi-C for cervical disc replacement (MIB70)

    NICE has developed a medtech innovation briefing (MIB) on Mobi-C for cervical disc replacement

    Medtech innovation briefing
    Published
    28 June 2016

  15. Apremilast for treating active psoriatic arthritis (TA372)

    This guidance has been updated and replaced by NICE technology appraisal guidance 433.

    Technology appraisal guidance
    Published
    16 December 2015